Skip to content

Category: 1

Creative science: Exhibition “Alzheimer’s Research Meets Art” provides insights into the world of biomedicine

14.10.2025

On Tuesday, October 7, Prof. Philipp Beckhove opened the exhibition of paintings by Prof. Stefan Rüdiger with a festive vernissage: Bright colors shine against a dark blue backdrop in the foyer of the main entrance at Regensburg University Hospital, encouraging visitors to learn about current Alzheimer’s research. The exhibition is open to the public until October 29, and admission is free of charge.

CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges

26.09.2025

In a recent article published in “Nature Reviews Gastroenterology & Hepatology”, LIT scientist Prof. Hinrich Abken comprehensively reviews the state-of-the art in chimeric antigen receptor (CAR) T cell therapy in gastrointestinal tumors and discusses challenges and emerging solutions to overcome treatment resistance of solid tumors. This overview is especially important for oncologists, immunologists, and medical researchers interested in cellular therapies against cancer.

SPD Politician Ruth Waldmann, MdL, Visits Leibniz Institute for Immunotherapy (LIT)

17.09.2025

In July, Ruth Waldmann, a member of the Bavarian State Parliament for the SPD and representing the district of Upper Bavaria, visited the LIT in Regensburg, accompanied by her team. Discussions with the LIT’s Scientific Director, Prof. Philipp Beckhove, focused on scientific innovations, public funding, and the future of research in Germany.

CAR-T Cells in Solid Tumors: Overcoming Resistance Mechanisms for Effective Therapy

15.09.2025

In a recent article published in “Der Internist” (German), LIT scientists Dr. Markus Barden, Dr. Astrid Holzinger, and Prof. Hinrich Abken comprehensively review the challenges and emerging solutions for chimeric antigen receptor (CAR) T cell therapy in solid tumors. This overview is especially important for oncologists, immunologists, and medical researchers interested in cellular therapies against cancer.

LIT Scientist Awarded Highly Competitive Grant

11.09.2025

Gabriele Inchingolo, Ph.D. student in Prof. Luca Gattinoni’s lab at the Leibniz Institute for Immunotherapy, has been selected as one of the winners of Bruker’s inaugural Beacon Discovery Global Grant Program.

LIT Retreat 2025

09.09.2025

The LIT Retreat took place on July 28 and 29, 2025 at Haus Bayerischer Wald in Lam.

LIT PhD Student Awarded Prestigious Scholarship

14.08.2025

Julia Englbrecht, a doctoral student at the Research Group “Epigenetic Immuno-oncology”, headed by Dr. Christian Schmidl, has been awarded the highly competitive doctoral scholarship by the “Studienstiftung des deutschen Volkes”.